| Literature DB >> 28661033 |
B Fujita1,2,3, W-H Zimmermann1,2.
Abstract
There is a pressing need for the development of advanced heart failure therapeutics. Current state-of-the-art is protection from neurohumoral overstimulation, which fails to address the underlying cause of heart failure, namely loss of cardiomyocytes. Implantation of stem cell-derived cardiomyocytes via tissue-engineered myocardium is being advanced to realize the remuscularization of the failing heart. Here, we discuss pharmacological challenges pertaining to the clinical translation of tissue-engineered heart repair with a focus on engineered heart muscle (EHM).Entities:
Mesh:
Substances:
Year: 2017 PMID: 28661033 PMCID: PMC5657241 DOI: 10.1002/cpt.724
Source DB: PubMed Journal: Clin Pharmacol Ther ISSN: 0009-9236 Impact factor: 6.875